UNSPSC 51434820: Tenosal

This classification denotes a calcium channel blocker with the molecular formula C12H8O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EEK88K197T, chemically known as 2-thiophenecarboxylic acid, ester with salicylic acid but generally known as tenosal, which bears US NIH Compound Identifier 65838. European Medicines Agency schedules Tenosal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10898MIG.

UNSPSC 51434820 Tenosal is a Commodity code encompassing emergency and clinical medications supplied to state and local public health and safety agencies. State and local governments procure specific pharmaceutical products under this code for use by fire rescue services, public health programs, and hospital systems — typically branded or generic medications with defined NDC codes, strength specifications, packaging requirements, and shelf-life conditions. Recent solicitations show purchases of individual medication line items (epinephrine, adenosine, diltiazem, labetalol) in unit quantities ranging from hundreds to thousands, with firm pricing, delivery timelines of ten calendar days or less, expiration-date warranties of nine months or more, and one-year base terms with renewal options. Issuing bodies include municipal purchasing departments (City of Tampa), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mix reflects both direct-buy procurement by individual fire and rescue departments and larger framework agreements through cooperative purchasing vehicles that aggregate demand across state and local members.

Recent activity spans Florida, Texas, Minnesota, and Oregon, with the most visible opportunities in the first half of 2026. The City of Tampa issued an IFB (Bid No. 26P00188) for Advanced Life Support Medications on April 24, 2026, with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00; this solicitation includes a 5 percent bid discount for Small Local Business Enterprise participation. Texas HHS posted an RFI (HHS0017013) on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling future formal solicitations for statewide pharmacy benefit contracting. MMCAP issued an RFP (S1070000015802) due March 26, 2026 for generic multi-source pharmaceuticals and OTC products to be distributed through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) across participating state and local facilities in multiple states, with contract terms of two years effective July 1, 2026. Cooperative purchasing frameworks appear to be the dominant vehicle for volume procurement, with performance requirements including cGMP certification, DSCSA compliance, EDI capability, and comprehensive insurance coverage.